ArticlePloS one2025
Genetic association of microRNA-146a polymorphisms with the severity of coronary artery lesions in acute myocardial infarction.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymorphisms situated within the microRNA-146a gene have been extensively reported to fulfill a crucial regulatory function in controlling inflammatory responses and modulating gene expression. More recently, these specific genetic variants have also been implicated in the pathogenesis of coronary artery lesions; nevertheless, the current body of available evidence remains notably sparse.
objectivesTo investigate the characteristics of the microRNA-146a gene polymorphisms rs2431697, rs57095329, and rs2910164, and their association with the severity of coronary artery lesions. MATERIALS AND
methodsThis comparative cross-sectional study included patients with acute myocardial infarction (AMI) and a control group, recruited from two hospitals in Can Tho City, Vietnam, between October 2023 and May 2025. All participants underwent clinical evaluation and coronary angiography. Subsequently, the microRNA-146a gene polymorphisms-rs2431697, rs57095329, and rs2910164-were analyzed using gene sequencing.
resultsA total of 249 patients were included in the AMI group and 249 in the control group. The mean age of the patient cohort (66.65 ± 10.89 years) was similar to that of the controls (66.67 ± 14.12 years). Analysis of the rs2910164 polymorphism showed a lower frequency of the GG genotype in the AMI group compared with the control group (14.9% vs. 20.9%, p < 0.05), and all three SNPs met Hardy-Weinberg equilibrium criteria. Among patients with AMI, 30.5% had three-vessel coronary artery disease, and severe stenosis (≥90% luminal narrowing) was present in 78.3% of cases. Multivariate analysis demonstrated that the rs2431697 CC + TC genotype (OR = 0.10), the rs2910164 GG + CG genotype (OR = 3.23), diabetes mellitus (OR = 5.14), dyslipidemia (OR = 4.01), smoking (OR = 5.16), NT-proBNP ≥ 300 pg/mL (OR = 8.69), a GRACE score > 140 (OR = 10.82), and a TIMI score > 4 (OR = 6.50) were independent predictors of severe coronary stenosis (p < 0.05).
conclusionPatients with acute myocardial infarction had a lower prevalence of the GG genotype of the rs2910164 polymorphism compared with the control group. The rs2910164 polymorphism of microRNA-146a-particularly genotypes carrying the G allele-along with a history of diabetes mellitus, dyslipidemia, smoking, NT-proBNP ≥ 300 pg/mL, a GRACE score > 140, and a TIMI score > 4 were identified as independent predictors of severe coronary artery stenosis. In contrast, the rs2431697 polymorphism with genotypes carrying the C allele was found to be a protective factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.